TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06667843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Management
Description: Behavioral intervention for lifestyle change

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Management
Description: Behavioral intervention for lifestyle change

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Full access to DTx function in the app, and digital follow up/communication with helthcare professionals at the Healthy Lives Center

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control
Description: Basic access to the app (daily logging functions). No digital follow up or communication with healthcare professionals at the Healthy Lives Center.
Study: NCT06668285

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: no intervention
Description: no intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parental presence
Description: parental presence
Study: NCT06668298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine
Description: The formula for postoperative analgesia pump is oliceridine 0.4mg · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfentanil
Description: The analgesic regimen for the sufentanil group is sufentanil 2 µ g · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.
Study: NCT06666907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smilefy
Description: AI based DSD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOCAD
Description: Conventional DSD software
Study: NCT06667102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategic and Interactive Signing Instruction
Description: SISI centers on deaf children producing sign language compositions to communicate their messages with identified audiences, and teachers utilizing strategic and interactive approaches to bring attention to target sign language skills by consciously monitoring and manipulating language to create desired meanings grounded in socially shared understandings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategic and Interactive Signing Instruction
Description: SISI centers on deaf children producing sign language compositions to communicate their messages with identified audiences, and teachers utilizing strategic and interactive approaches to bring attention to target sign language skills by consciously monitoring and manipulating language to create desired meanings grounded in socially shared understandings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategic and Interactive Signing Instruction
Description: SISI centers on deaf children producing sign language compositions to communicate their messages with identified audiences, and teachers utilizing strategic and interactive approaches to bring attention to target sign language skills by consciously monitoring and manipulating language to create desired meanings grounded in socially shared understandings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategic and Interactive Signing Instruction
Description: SISI centers on deaf children producing sign language compositions to communicate their messages with identified audiences, and teachers utilizing strategic and interactive approaches to bring attention to target sign language skills by consciously monitoring and manipulating language to create desired meanings grounded in socially shared understandings.
Study: NCT06667427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve transfer techniques
Description: Participants will undergo facial nerve reconstruction using nerve transfer techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve transfer techniques
Description: Participants will undergo facial nerve reconstruction using nerve transfer techniques
Study: NCT06459349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exteroceptive and proprioceptive sensory stimulation training
Description: Patients in this group will receive intervention exteroceptive and proprioceptive sensory stimulation for 50 minutes per session, 03 times a week, for 06 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sensorimotor therapy group
Description: Patients will receive sensorimotor therapy for 50 minutes per session, 03 times a week, for 06 weeks
Study: NCT06616675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darifenacin
Description: Anticholinergic drug therapy for OAB treatment - Darifenacin, 15mg/day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation - Sacral nerve stimulation
Description: Neurodyn Portable TENS FES neuromuscular stimulation device in an outpatient clinic. Two self-adhesive electrodes (5x9cm) were used, positioned one in each gluteal region, below the iliac spine to apply low-frequency biphasic current with 10 Hz. Pulse duration of 0.5 milliseconds was applied for 40 minutes with continuous stimulation, 3 times a week, for 20 sessions.
Study: NCT06665919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP2C19 Genotype-Guided Clopidogrel Treatment
Description: Clopidogrel as a component of preventive antiplatelet treatment such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel
Description: An antiplatelet drug alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the non-vitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor, or prasugrel).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Conventional Clopidogrel Treatment
Description: Clopidogrel as a component of preventive antiplatelet treatment such as double antiplatelet treatment (DAPT), or clopidogrel combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel).
Study: NCT06621173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNF4α srRNA
Description: HNF4α srRNA will be administered intravenously for the treatment of metastatic colorectal cancer. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.
Study: NCT06668350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking outcomes
Description: Participants will be assessed on several smoking outcomes including puffing behavior, subjective effects, and exhaled carbon monoxide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking outcomes
Description: Participants will be assessed on several smoking outcomes including puffing behavior, subjective effects, and exhaled carbon monoxide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking outcomes
Description: Participants will be assessed on several smoking outcomes including puffing behavior, subjective effects, and exhaled carbon monoxide
Study: NCT06618716

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)
Description: Intravenous administration of endotoxin (0.8 ng/kg body weight)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placcebo
Description: Placebo injection of 0.9% NaCl
Study: NCT05668936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single oral dose of Moxifloxacin film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single oral dose of Moxifloxacin film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-placebo
Description: Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-placebo
Description: Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-placebo
Description: Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.
Study: NCT06618196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LR20062
Description: DTaP-HepB-IPV-Hib vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LR20062
Description: DTaP-HepB-IPV-Hib vaccine
Study: NCT05632536

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SACRAL ESP AND CAUDAL BLOCK
Description: Application of ultrasound-guided sacral erector spinae plane (ESP) block or ultrasound-guided caudal block with 1mL/kg 0.25% bupivacaine (local anesthetic) to patients
Study: NCT06618196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LR20062
Description: DTaP-HepB-IPV-Hib vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-HepB-IPV-Hib vaccine
Description: Control hexavalent vaccine
Study: NCT06623617

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Three-dimensional breathing training
Description: Engage in app-based three-dimensional breathing training and learn to use a biofeedback pressure device at home for proper and effective training. They will also be guided to log their daily training, manually inputting data such as duration and frequency. A virtual assistant will provide real-time feedback based on this data, including encouragement and adjustments to training intensity.
Study: NCT05632536

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SACRAL ESP AND CAUDAL BLOCK
Description: Application of ultrasound-guided sacral erector spinae plane (ESP) block or ultrasound-guided caudal block with 1mL/kg 0.25% bupivacaine (local anesthetic) to patients
Study: NCT06623617

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control group：Health education
Description: Provide participants with health education, which is conducted one-on-one by researchers during the recruitment of mothers. The content includes the etiology and risk factors of PPSUI (Pelvic Organ Prolapse during Straining), the benefits and precautions of pelvic floor muscle exercises and breathing techniques, as well as the implementation methods.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control group：Health education
Description: Provide participants with health education, which is conducted one-on-one by researchers during the recruitment of mothers. The content includes the etiology and risk factors of PPSUI (Pelvic Organ Prolapse during Straining), the benefits and precautions of pelvic floor muscle exercises and breathing techniques, as well as the implementation methods.
Study: NCT06683651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1013800 ophthalmic solution
Description: Investigational Product: 0.1% STN1013800 ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STN1013800 ophthalmic solution Liquid Base, without STN1013800
Description: Placebo control: STN1013800 ophthalmic solution Liquid Base, without STN1013800
Study: NCT06682312

Intervention type: DEVICE
Intervention: Non-invasive blood pressure
Description: Manual blood pressure via sphygmomanometer~Or~Non invasive blood pressure via earlyvue VS30 Monitor
Study: NCT06619067

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PROBAFLOR
Description: PROBAFLOR is a food supplement made up of 11 bacterial strains and inulin. The bacterial strains present are: Bifidobacterium lactis BLC1, Lactococcus lactis LL82, Lactobacillus plantarum 14D, Lactobacillus acidophilus LA1, Streptococcus thermophilus Z57, Bifidobacterium longum SP54, Lactobacillus rhamnosus SP1, Lactobacillus bulgaricus LB2, Bifidobacterium bifidum SP9,Lactobacillus salivarius SP2, Lactobacillus casei BGP93.
Study: NCT06609499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible-tip Bougie
Description: The device is used for intubation and then the manikin is ventilated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gum-elastic Bougie
Description: The device is used for intubation and then the manikin is ventilated
Study: NCT06619067

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06618456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR dive (with Hypnosis)
Description: Participants experience a VR dive through a friendly underwater world. They get a trance induction via audio.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR dive (without Hypnosis)
Description: Participants experience a VR dive through a friendly underwater world. They are informed that this part of the VR is a familiarization phase to the VR and they do not get a trance induction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Height exposure
Description: The participants go through a height exposure. They start at the ground level of a virtual city and move upwards in 3 meter steps until they reach a height of 60 meters. Participants focus on a yellow spot on a balcony in front of them, so that they can recognise the depth perimeter.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Height exposure
Description: The participants go through a height exposure. They start at the ground level of a virtual city and move upwards in 3 meter steps until they reach a height of 60 meters. Participants focus on a yellow spot on a balcony in front of them, so that they can recognise the depth perimeter.
Study: NCT01048983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
Study: NCT06622356

Intervention type: OTHER
Intervention: MRI with Eovist
Description: The study was retrospective and did not design an intervention

Intervention type: OTHER
Intervention: MRI with Eovist
Description: The study was retrospective and did not design an intervention
Study: NCT06623201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid HCL (ALA)
Description: Prior to ALA application, the areas will be cleaned with alcohol and debrided gently with prep tape. ALA will then be applied to each of the study lesions and allowed to incubate for 3 hours with occlusion prior to the PDT.
Study: NCT06624176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionix ShotBlocker
Description: This is a hospital-approved device used as standard-of-care in older children and adults to reduce pain during painful procedures. It is not considered established standard-of-care in the infant cohort.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddling
Description: Standard of care swaddling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Swaddling
Description: Standard of care swaddling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose administration
Description: Standard of care sucrose administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose administration
Description: Standard of care sucrose administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masimo Rad-97 Oximeter probe
Description: Oximeter probe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Masimo Rad-97 Oximeter probe
Description: Oximeter probe
Study: NCT01048983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
Study: NCT06624163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OHWL Clinic Activities (Standard of Care)
Description: Following a directed history and physical at the initial visit, the OHWL Care provider (OCP) develops a medical and weight management plan, which includes laboratory testing (such as for Hemoglobin A1C (HbA1c), consultant referrals (e.g. sleep, heart failure clinics) and referral to nutritionists and physical therapy (PT). The OCP begins the process of establishing patient goals, which will be followed up by the coach. The OCP reviews patient progress with the goals during face-to-face visits (some by telehealth) at two, four and six months. As part of the standard initial clinic evaluation, a medical assistant evaluates grip strength (using a hand dynamometer) the timed up and go mobility test; these are repeated at the 6-month visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach Activities
Description: A patient coach follows patients outside of clinic to ensure adherence with referral appointments and use of recommended community services. The coach assesses the participant at baseline, 3 months, and 6 months using the Patient-Specific Functional Scale and follows up with patients via phone over 6 months. The coach utilizes S.M.A.R.T. (Specific, Measurable, Achievable, Relevant, Time-bound) goals to facilitate, for example, transportation, barriers to scheduling, etc. The coach follows up on specialist referral recommendations, physical therapy, and nutrition program, as well as social work recommendations. Barriers and facilitators to program adherence are identified and addressed.
Study: NCT06623201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLU-U device model 4170E
Description: Participants will be subjected to dose illumination with blue light (BLU-U Model 4170E) at a power fluence of 20 mW/cm2 for a total time of 16 minutes and 40 seconds (1,000 seconds). This will result in a total light delivery dose of 20 J/cm2.
Study: NCT06625996

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate loading
Description: Preoperative carbohydrate loading

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: carbohydrate loading
Description: Preoperative carbohydrate loading
Study: NCT06624436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 6mg in 10mL NaCl 0.9% i.v. bolus + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab 600mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra 200mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bolus of 10mL NaCl 0.9% placebo + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LPS
Description: This is a non-investigational product. It is used as challenge agent to achieve a controlled inflammatory state.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LPS
Description: This is a non-investigational product. It is used as challenge agent to achieve a controlled inflammatory state.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LPS
Description: This is a non-investigational product. It is used as challenge agent to achieve a controlled inflammatory state.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LPS
Description: This is a non-investigational product. It is used as challenge agent to achieve a controlled inflammatory state.
Study: NCT06625879

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block (SAPB)
Description: Group I: (Serratus Anterior Plane Block (SAPB) Group) (n=15):~The patient will lay on her side with arm brought forward, the linear US transducer probe (10-12 MHz) will be placed in the midaxillary line and then moved caudal from second rib until the sixth intercostal space. At this point, the subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction. In-plane technique will be used until the tip of the needle placed between the serratus anterior muscle and the external intercostal muscle (deep SABP) . A volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Midpoint transverse process to pleura (MTP) block
Description: In the lateral postion, the T4 spine will be counted by ultrasound, and high frequency linear US transducer probe (10-12 MHz) will be placed longitudinally, approximately 2.5 cm lateral to the midline the needle will be advanced in plane from cranial to caudal direction. The desired end point for the needle tip will be the midpoint of the line between the posterior border of the transverse process of T4 and the pleura(injection will be deep (anterior) to the posterior aspect of the vertebral transverse process but superficial to the superior costotransverse ligment),the needle tip dose not enter the paravertebral space , a volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection,pleural displacement and bowing of erector spinae will be observed at the side of injection .
Study: NCT06624397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAREFREE Carer's Programme
Description: This programme was developed to provide carers with an opportunity to develop an understanding of Anorexia from a Biopsychosocial framework, taking into account the complex array of biological, psychological and social/environmental factors associated with the development and maintenance of this disorder. CAREFREE programme is unique in its focus on providing a framework for understanding AN from a Schema - Compassion Focused framework, incorporating psychoeducation in regard to both Anorexia Nervosa and Carer Burnout. The programme has a relational focus, with an emphasis on improving emotional fluency, family communication skills and self-other compassion.